Dr. Mikhail Blaggosklonny’s Role In The Fields Of Cancer And Aging
Dr. Mikhail Blagosklonny, Ph.D., is a professor and researcher. He is from Russia and earned both his medical degree in internal medicine as well as his Ph.D. in experimental medicine from the First Pavlov State Medical University of St. Petersburg. When he was named as an associate professor at the New York Medical School he immigrated to the United States. From 2002 to 2009 he worked at the Ordway Research Institute as a senior scientist. In 2009 he joined Roswell Cancer Institute in Buffalo, New York and is a professor of oncology as well as a cancer and aging researcher.
Dr. Blagosklonny’s cancer research is specialized in targeted cancer therapies that destroy cancer cells while not affecting healthy tissue, blood, and bones. He also clinically investigates oncogenes and tumor suppressors. This research has also led him to other age-related diseases and even the process of aging itself. Rapamycin is a cancer drug that is often used to treat cancer. Dr. Blagosklonny believes this drug can slow down or even halt the aging process as it could play a role in TOR signaling which is a primary cause of aging. Follow Mikhail on Google Scholar
There are several peer-reviewed scientific journals that Dr. Mikhail Blagosklonny is an editor or founder of. Among his biggest is Oncotarget which he co-founded and serves as a co-editor in chief. Oncotarget is a multidisciplinary medical journal that is published online on a weekly basis. Other journals he has a hand in includes Cancer Biology & Therapy, Cell Death and Differentiation, The American Journal of Pathology, Aging, Cell Cycle, and Autophagy.
In addition to being an editor, Dr. Blagosklonny has also written many papers, reviews, and book chapters himself. He has over 300 works credited to him that cover both cancer and age-related topics. Many of his research papers are on Rapamycin and TOR Signaling. Visit classroomvoices.org to read more about Mikhail.